We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

Nestlé Subsidiary Acquires U.K. Medical Food Company

February 2, 2011: 12:34 PM EST

Nestlé Health Science has completed the acquisition of CM&D Pharma Ltd. (CM&D), a British company that develops medical foods and other products targeting patients with kidney disease, inflammatory bowel disease, and colon cancer. CM&D is a portfolio company of venture capital fund Inventages Group. CM&D’s leading product, Fostrap, is a chewing gum for kidney patients with elevated levels of phosphate in the blood (hyperphosphatemia), which contributes to vascular calcification and an increased risk of cardiac mortality, as well as mineral and bone disorders. Clinical trials of Fostrap are ongoing, though preliminary data are promising, according to Nestlé.

"Nestlé Health Science to develop dietary solution for kidney patients – CM&D acquisition", Nestle press release, February 02, 2011, © Nestle
Vitality & Better Living
United Kingdom
Companies, Organizations
Deals, M&A, JVs, Licensing
Press Release
Products & Brands
Developed by Yuri Ingultsov Software Lab.